Results 101 to 110 of about 326,057 (302)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses

, 2007
The molecular mechanisms whereby the CD45 tyrosine phosphatase (PTPase) regulates T cell receptor (TCR) signaling responses remain to be elucidated. To investigate this question, we have reconstituted CD45 (encoded by Ptprc)-deficient mice, which display
Cooper, Joanne C, Alexander, Denis R, Cassady-Cain, Robin L., Salmond, Robert J., Tandon, Panna, Roche-Molina, Marta, Carret, Céline K., Holmes, Nick, McNeill, Louise, Cassady-Cain, Robin, Cooper, Joanne C., Alexander, Denis R., Carret, Celine K   +12 more
core   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Allan, Elaine K., Mueller-Tidow, Carsten, Nicolini, Franck E., Bhatia, Ravi, Brunton, Valerie G, Myssina, Svetlana, Hamilton, Ashley, Mysina, Svetlana, Müller-Tidow, Carsten, Koschmieder, Steffen, Allan, Elaine K, Helgason, G. Vignir, Helgason, G Vignir, Brunton, Valerie G., Schemionek, Mirle, Zhang, Bin, Holyoake, Tessa L., Holyoake, Tessa L, Nicolini, Franck E   +18 more
core   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistance in breast cancer [PDF]

, 2009
HER-2 gene amplification or overexpression occurs in approximately 25 % of breast cancers, and trastuzumab (Tmab) is a monoclonal antibody currently used to treat patients with HER-2-overexpressing breast cancer.
Browne, Brigid
core  

MiR‐513a promotes human erythroid differentiation by modulating c‐Jun

FEBS Open Bio, EarlyView.
During early human erythropoiesis, miR‐513a promoted erythroid differentiation in primary human CD34+ hematopoietic stem‐progenitor cells and human TF‐1 erythroleukemic cells by indirectly decreasing c‐Jun and phospho‐c‐Jun expression, which are associated with increased GATA1 expression.
MinJung Kim, Brittany Taylor, Shannon Bolten, Christian L. Eberly, Mahliya Abdurahman, T. Michael Creed, Acong Yang, Taylor L. Hatchet, Tristan Dyson, Shuo Gu, Curt I. Civin, Tami J. Kingsbury   +11 more
wiley   +1 more source

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

BMC Cancer, 2011
Background Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib.
Sun Jin, Zhang Zhiyuan, Wang Tongshan, Chen Xiaofen, Guo Renhua, Shu Yongqian   +5 more
doaj   +1 more source

Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling

, 2001
The "metabolic cocktail" comprising glucose-insulin-potassium administrated at reperfusion reduces infarct size in the in vivo rat heart. We propose that insulin is the major component mediating this protection and acts via Akt prosurvival signaling ...
Sack, M.N., Yellon, D.M., Jonassen, A.K., Mjøs, O.D.   +3 more
core  

Molecular dynamics simulations of positively selected codons in FcγRI reveal novel biochemical binding properties

FEBS Open Bio, EarlyView.
Evolutionary analysis across 32 placental mammals identified positive selection at residues H148 and W149 in the immune receptor FcγR1. Ancestral reconstruction combined with molecular dynamics simulations reveals how these mutations may influence receptor structure and dynamics, providing insight into the evolution of antibody recognition and immune ...
David A. Young, Omar Arias‐Gaguancela, Fiona Gibson, Morgan Grainger, Jodie Score, Amit Nathubhai, Mauricio Cafiero, Lee Richard Machado   +7 more
wiley   +1 more source

Trastuzumab is not a tyrosine kinase inhibitor [PDF]

Nature Reviews Cardiology, 2015
Nishant, Mohan, Wen Jin, Wu
openaire   +2 more sources